u87 fluc  (ATCC)

Journal: Scientific Reports

Article Title: Loco-regional treatment with temozolomide-loaded thermogels prevents glioblastoma recurrences in orthotopic human xenograft models

doi: 10.1038/s41598-023-31811-5

Figure Lengend Snippet: IC 50 for TMZ on cell viability in U87 MG-Red-FLuc human glioblastoma cells by cell counts. The concentration-dependent inhibitory dose-curve data was plotted as log percentage inhibition normalized to controls with applied curve non-fit calculated using GraphPad Prism. Results are shown as the mean of at least three independent experiments ± SEM.

Article Snippet: To track tumor growth in an orthotopic mouse model for glioblastoma, we decided to use commercially available human cancer cells expressing a very bright red-shifted luciferase (Red-FLuc), U87-MG-Red-FLuc cells ( https://www.perkinelmer.com/product/ivisbrite-u87mg-red-f-luc-bw124577 ).

Techniques: Concentration Assay, Inhibition

Journal: Scientific Reports

Article Title: Loco-regional treatment with temozolomide-loaded thermogels prevents glioblastoma recurrences in orthotopic human xenograft models

doi: 10.1038/s41598-023-31811-5

Figure Lengend Snippet: In vitro effect of the isolated components and of assembled new gel formulations on Glioblastoma cells. ( a ) U87-MG-Red-FLuc cells were treated with cell medium (CTRL), mesoporous SiO 2 nanoparticles (SiO 2 ) and polycaprolactone microparticles (PCL) for 24 h, causing no significant reduction in viable cells number. ( b ) U87 MG-Red-FLuc cells were treated with cell medium (CTRL), the empty thermogel (THG), and the thermogels containing mesoporous SiO 2 nanoparticles (THG@SiO 2 ) and polycaprolactone microparticles (THG@PCL) for 24 h, causing no significant reduction in viable cells number. ( c ) TMZ-containing SiO 2 nanoparticles and PCL microparticles efficiently release active drug into the cell medium to induce cell death after 24 h treatment in U87 MG-Red-FLuc cells (*p < 0.05). ( d ) THG@SiO 2 -TMZ and THG@PCL-TMZ efficiently release active TMZ into the cell medium to induce cell death after 24 h treatment in U87-MG-Red-FLuc cells (* p < 0.05; ** p < 0.005).

Article Snippet: To track tumor growth in an orthotopic mouse model for glioblastoma, we decided to use commercially available human cancer cells expressing a very bright red-shifted luciferase (Red-FLuc), U87-MG-Red-FLuc cells ( https://www.perkinelmer.com/product/ivisbrite-u87mg-red-f-luc-bw124577 ).

Techniques: In Vitro, Isolation

Journal: Scientific Reports

Article Title: Loco-regional treatment with temozolomide-loaded thermogels prevents glioblastoma recurrences in orthotopic human xenograft models

doi: 10.1038/s41598-023-31811-5

Figure Lengend Snippet: In vivo efficacy of TMZ-based therapeutic thermogels using a GBM resection and recurrence mouse model. ( a ) Experimental timeline for studying the in vivo anticancer activities of gel-based local glioblastoma treatments. Two independent experiments comparing empty THG with THG@SIO 2 -TMZ and THG@PCL-TMZ, respectively, were performed (n = 5). Results were next merged resulting in n = 8 for THG, n = 3 for THG@SIO 2 -TMZ and n = 4 for THG@PCL-TMZ, considering drop-outs due to the severity of the procedure. ( b ) Representative BLI images of mice bearing U87-MG-Red-FLuc implantation in the subcortical striatal region. After primary tumor resection, THG@SIO 2 -TMZ, THG@PCL-TMZ or empty THG were applied. ( c ) Tumor growth was directly related to the increment of luminescence signal normalized to baseline (day 2 after resection, corresponding to Time 0 in panels A and B) and recorded at days 7 (Time 1), 14 (Time 2) and 21 (Time 3) after resection, in THG, THG@SiO 2 -TMZ and THG@PCL-TMZ groups. Tumor growth was expressed as fold increase [Lum(tx)−Lum (t0)/Lum (t0)]. THG@SIO 2 -TMZ or THG@PCL-TMZ reduced tumor recurrences when compared to empty THG treatment (*p < 0.05; two-ways ANOVA p < 0.05). ( d ). Luminescence signals from control (empty THG) animals on day 21 are significantly higher (*p < 0.05; Kruskal–Wallis test p < 0.004). ( e ) Site of the resection in relation to the Paxinos representation of brain coronal section at the injection coordinate (− 0.5 mm). Representative images of H&E-stained brain sections collected 21 days after tumor resection and gel application from mice receiving either THG@SIO 2 -TMZ, THG@PCL-TMZ or empty THG (control animals) show the growth of the tumor mass to the areas adjacent to the cancer cells injection site.

Article Snippet: To track tumor growth in an orthotopic mouse model for glioblastoma, we decided to use commercially available human cancer cells expressing a very bright red-shifted luciferase (Red-FLuc), U87-MG-Red-FLuc cells ( https://www.perkinelmer.com/product/ivisbrite-u87mg-red-f-luc-bw124577 ).

Techniques: In Vivo, Control, Injection, Staining

Journal: Scientific Reports

Article Title: Loco-regional treatment with temozolomide-loaded thermogels prevents glioblastoma recurrences in orthotopic human xenograft models

doi: 10.1038/s41598-023-31811-5

Figure Lengend Snippet: IC 50 for TMZ on cell viability in U87 MG-Red-FLuc human glioblastoma cells by cell counts. The concentration-dependent inhibitory dose-curve data was plotted as log percentage inhibition normalized to controls with applied curve non-fit calculated using GraphPad Prism. Results are shown as the mean of at least three independent experiments ± SEM.

Article Snippet: Glioblastoma U87-MG-Red-FLuc cell line for In Vivo Imaging System (IVIS) were purchased by Perkin Elmer.

Techniques: Concentration Assay, Inhibition

Journal: Scientific Reports

Article Title: Loco-regional treatment with temozolomide-loaded thermogels prevents glioblastoma recurrences in orthotopic human xenograft models

doi: 10.1038/s41598-023-31811-5

Figure Lengend Snippet: In vitro effect of the isolated components and of assembled new gel formulations on Glioblastoma cells. ( a ) U87-MG-Red-FLuc cells were treated with cell medium (CTRL), mesoporous SiO 2 nanoparticles (SiO 2 ) and polycaprolactone microparticles (PCL) for 24 h, causing no significant reduction in viable cells number. ( b ) U87 MG-Red-FLuc cells were treated with cell medium (CTRL), the empty thermogel (THG), and the thermogels containing mesoporous SiO 2 nanoparticles (THG@SiO 2 ) and polycaprolactone microparticles (THG@PCL) for 24 h, causing no significant reduction in viable cells number. ( c ) TMZ-containing SiO 2 nanoparticles and PCL microparticles efficiently release active drug into the cell medium to induce cell death after 24 h treatment in U87 MG-Red-FLuc cells (*p < 0.05). ( d ) THG@SiO 2 -TMZ and THG@PCL-TMZ efficiently release active TMZ into the cell medium to induce cell death after 24 h treatment in U87-MG-Red-FLuc cells (* p < 0.05; ** p < 0.005).

Article Snippet: Glioblastoma U87-MG-Red-FLuc cell line for In Vivo Imaging System (IVIS) were purchased by Perkin Elmer.

Techniques: In Vitro, Isolation

Journal: Scientific Reports

Article Title: Loco-regional treatment with temozolomide-loaded thermogels prevents glioblastoma recurrences in orthotopic human xenograft models

doi: 10.1038/s41598-023-31811-5

Figure Lengend Snippet: In vivo efficacy of TMZ-based therapeutic thermogels using a GBM resection and recurrence mouse model. ( a ) Experimental timeline for studying the in vivo anticancer activities of gel-based local glioblastoma treatments. Two independent experiments comparing empty THG with THG@SIO 2 -TMZ and THG@PCL-TMZ, respectively, were performed (n = 5). Results were next merged resulting in n = 8 for THG, n = 3 for THG@SIO 2 -TMZ and n = 4 for THG@PCL-TMZ, considering drop-outs due to the severity of the procedure. ( b ) Representative BLI images of mice bearing U87-MG-Red-FLuc implantation in the subcortical striatal region. After primary tumor resection, THG@SIO 2 -TMZ, THG@PCL-TMZ or empty THG were applied. ( c ) Tumor growth was directly related to the increment of luminescence signal normalized to baseline (day 2 after resection, corresponding to Time 0 in panels A and B) and recorded at days 7 (Time 1), 14 (Time 2) and 21 (Time 3) after resection, in THG, THG@SiO 2 -TMZ and THG@PCL-TMZ groups. Tumor growth was expressed as fold increase [Lum(tx)−Lum (t0)/Lum (t0)]. THG@SIO 2 -TMZ or THG@PCL-TMZ reduced tumor recurrences when compared to empty THG treatment (*p < 0.05; two-ways ANOVA p < 0.05). ( d ). Luminescence signals from control (empty THG) animals on day 21 are significantly higher (*p < 0.05; Kruskal–Wallis test p < 0.004). ( e ) Site of the resection in relation to the Paxinos representation of brain coronal section at the injection coordinate (− 0.5 mm). Representative images of H&E-stained brain sections collected 21 days after tumor resection and gel application from mice receiving either THG@SIO 2 -TMZ, THG@PCL-TMZ or empty THG (control animals) show the growth of the tumor mass to the areas adjacent to the cancer cells injection site.

Article Snippet: Glioblastoma U87-MG-Red-FLuc cell line for In Vivo Imaging System (IVIS) were purchased by Perkin Elmer.

Techniques: In Vivo, Control, Injection, Staining

Journal: bioRxiv

Article Title: Swift Formation of Optimal Single Spheroids towards In-Vitro 3-Dimensional Tumour Models

doi: 10.1101/2021.12.16.472941

Figure Lengend Snippet: IncuCyte S3 live cell system (4×) Live spheroids images analysis shows the proliferation curves of the confluence ratio of U87 single spheroid upon using the protocol steps. The first triplicate failed to convert the aggregates to spheroids without using the washing solution. However, following the protocol showed consistent reproducibility for the single spheroids on three triplicates 2, 3, and 4. The images show the difference between the shape of the aggregates and the successful shape of the spheroid.

Article Snippet: The human glioblastoma U87 MG-Red-FLuc (Bioware Brite, PerkinElmer, Waltham, Massachusetts, USA) was the authorized cell line in all experiments.

Techniques:

Journal: bioRxiv

Article Title: Swift Formation of Optimal Single Spheroids towards In-Vitro 3-Dimensional Tumour Models

doi: 10.1101/2021.12.16.472941

Figure Lengend Snippet: IncuCyte S3 live cell system (4×) Live spheroids images analysis shows (A) the proliferation curves of the confluence ratio of U87 single spheroid for four spheroids shrinked to the half size after 24 hours then grew over time. The images show the negative effect of using different type of plate. (B) the image shows the instant adherence of the cells when using different plate without washing. (C) The image shows the cells gathered when the anti-adherence solution. However, the plate material was not suitable to allow the tightness of the cells. A crack in the middle appeared after the centrifugation directly.

Article Snippet: The human glioblastoma U87 MG-Red-FLuc (Bioware Brite, PerkinElmer, Waltham, Massachusetts, USA) was the authorized cell line in all experiments.

Techniques: Centrifugation

Journal: bioRxiv

Article Title: Swift Formation of Optimal Single Spheroids towards In-Vitro 3-Dimensional Tumour Models

doi: 10.1101/2021.12.16.472941

Figure Lengend Snippet: Cell tightness and interaction analysis of U87 MG spheroids. H & E stain of spheroid slices from (A) the core area, and (B) top rim area of 7 days spheroid generated from 400 cells.

Article Snippet: The human glioblastoma U87 MG-Red-FLuc (Bioware Brite, PerkinElmer, Waltham, Massachusetts, USA) was the authorized cell line in all experiments.

Techniques: Staining, Generated

Journal: bioRxiv

Article Title: Swift Formation of Optimal Single Spheroids towards In-Vitro 3-Dimensional Tumour Models

doi: 10.1101/2021.12.16.472941

Figure Lengend Snippet: IncuCyte S3 live cell system (4×) Live spheroids images show the potential of using the protocol to obtain single spheroids from various cell lines. The comparison shows consistency in the mean size and similar standard deviation for 6 individual samples from each cell line (U87 MG, SF188, SEBTA-027 human brain tumours, DU145 prostate human tumour, and TRAMP-C1 prostate murine tumour). The scale bar is 400 µm.

Article Snippet: The human glioblastoma U87 MG-Red-FLuc (Bioware Brite, PerkinElmer, Waltham, Massachusetts, USA) was the authorized cell line in all experiments.

Techniques: Comparison, Standard Deviation

Journal: bioRxiv

Article Title: Swift Formation of Optimal Single Spheroids towards In-Vitro 3-Dimensional Tumour Models

doi: 10.1101/2021.12.16.472941

Figure Lengend Snippet: Expression of (A) E-cadherin and Beta Actin. (B) Vinculin and vimentin in U87MG cells grown either in a monolayer, or as spheroids derived from 400 cells for 24 hours and 10 days.

Article Snippet: The human glioblastoma U87 MG-Red-FLuc (Bioware Brite, PerkinElmer, Waltham, Massachusetts, USA) was the authorized cell line in all experiments.

Techniques: Expressing, Derivative Assay

Journal: Frontiers in Pharmacology

Article Title: Combined Therapy With Avastin, a PAF Receptor Antagonist and a Lipid Mediator Inhibited Glioblastoma Tumor Growth

doi: 10.3389/fphar.2021.746470

Figure Lengend Snippet: Morphological growth and luciferase activity in U87MG cells. Representative images of U87MG cells at 3 (A) , 36 (B) , and 72 (C) hours at 20x magnification after taking out of Cryofrizide. A luciferase receptor gene was used to tag the U87MG cells. Steady growth and attenuation of the morphological pattern of U87MG cells present at 36 and 72 h. (D) Detection of luciferase activity expressed in luciferase units (LFU) in U87MG and hRPE cells. Results are the average of three independent experiments.

Article Snippet: The human cell line U87 MG-Red-Flug (U87MG) containing a luciferase-expressing gene was purchased from PerkinElmer (Waltham, MA).

Techniques: Luciferase, Activity Assay

Journal: Frontiers in Pharmacology

Article Title: Combined Therapy With Avastin, a PAF Receptor Antagonist and a Lipid Mediator Inhibited Glioblastoma Tumor Growth

doi: 10.3389/fphar.2021.746470

Figure Lengend Snippet: (A) Experimental design, showing bregma level and site of tumor cell implantation in anesthetized athymic nude female mice, secured in a stereotactic head frame. (B) Timeline showing GBM implantation, imaging, and treatments. Mice underwent stereotactic implantation of the luciferase-modified U87MG cells on day 0 and were monitored during a 30-day survival period. Treatment was started on day 13 post-implantation. In vivo bioluminescent imaging was performed on days 13, 20, and 30 post-implantation. On day 30, mice were sacrificed, and ex vivo MRI was conducted on perfused brains.

Article Snippet: The human cell line U87 MG-Red-Flug (U87MG) containing a luciferase-expressing gene was purchased from PerkinElmer (Waltham, MA).

Techniques: Imaging, Luciferase, Modification, In Vivo, Ex Vivo

Journal: Frontiers in Pharmacology

Article Title: Combined Therapy With Avastin, a PAF Receptor Antagonist and a Lipid Mediator Inhibited Glioblastoma Tumor Growth

doi: 10.3389/fphar.2021.746470

Figure Lengend Snippet: Quantification of bioluminescent signals from tumors. Radiance (Radiance × 10 6 ) values from regions of interest in mice from all groups were averaged and compared on days 13, 20, and 30 following intracranial implantation of U87-Luc cells. Tumor-bearing mice treated with (A) LAU-0901, Avastin, LAU-0901 + Avastin and (B) ELV, ELV + LAU-0901, and ELV + Avastin were observed have significantly reduced tumorigenesis when compared to vehicle-treated mice. All values are mean ± SEM ( n = 5–7), * p < 0.05.

Article Snippet: The human cell line U87 MG-Red-Flug (U87MG) containing a luciferase-expressing gene was purchased from PerkinElmer (Waltham, MA).

Techniques: